POTE ankyrin domain family member MGenealiases: ACT · P704P · POTE14beta
Q-omics provides the consensus-scored POTEM profile across patient tissues and cancer cell-line models. POTEM expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, POTEM is differentially expressed in 1, with the highest sampling consensus in PRAD. Additionally, POTEM RNA expression shows 6,272 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight COAD, PRAD, and STAD as cancer lineages where POTEM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for POTEM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes POTEM survival associations across molecular data types. POTEM RNA expression shows survival associations in the most cancer types (13), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible POTEM RNA expression–survival associations across cancer types. High POTEM expression shows unfavorable associations in COAD, KIRC, PAAD, KICH and LUAD, but favorable associations in SCLC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for POTEM RNA expression.
This table summarizes POTEM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in PRAD for RNA.
This table ranks reproducible tumor–normal expression differences for POTEM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. POTEM shows higher tumor expression in PRAD. The PRAD box plot shows higher POTEM RNA expression in tumor versus normal tissue (log2 FC = +0.269, t-test p = .013).
This table shows molecular features associated with POTEM in patient tissues and cancer cell lines. In patient samples, POTEM shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, POTEM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and OESOPHAGUS.
